Trigger pSA predicting recurrence from positive choline PET/CT with prostate cancer after initial treatment

PURPOSE: To assess the relationship between the diagnostic accuracy of Choline positron emission tomography/computed tomography (PET/CT) and the trigger prostate-specific antigen (PSA) level in patients with a biochemical recurrence of prostate cancer. MATERIALS AND METHODS: A meta-analysis was conducted to synthesize data across multiple studies. RESULTS: The pooled sensitivity and specificity of choline PET/CT were 82% (95% Confidence Interval (CI):80–84%) and 92% (95%CI: 90–93%), respectively. The pooled sensitivity and specificity of (18)F-choline PET/CT were 81% (95%CI: 78–84%) and 90% (95%CI: 85–93%), respectively. The pooled sensitivity and specificity of (11)C-choline PET/CT were 83% (95% CI: 80–86%) and 92% (95% CI: 90–94%), respectively. The pooled detection rate of (18)F-choline PET/CT and (11)C-choline PET/CT were 58% (95% CI: 48–68%) and 58% (95%CI: 49–68%), respectively. CONCLUSIONS: Trigger PSA is an important risk factor for positive findings of Choline PET/CT and the detection rate of Choline PET/CT for recurrent prostate cancer increased in parallel with raises in PSA-values. Choline PET/CT got higher detection rate while the trigger PSA > 2ng/ml.